BRCT.F Stock Overview
Develops biological drugs for patients with disorders of the central nervous system in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for BRCT.F from our risk checks.
BioArctic AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 16.68 |
| 52 Week High | SEK 27.66 |
| 52 Week Low | SEK 12.94 |
| Beta | -0.25 |
| 11 Month Change | 11.82% |
| 3 Month Change | 1.61% |
| 1 Year Change | -26.36% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -36.70% |
Recent News & Updates
Recent updates
Shareholder Returns
| BRCT.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -16.6% | -3.7% | 0.3% |
| 1Y | -26.4% | 15.2% | 31.1% |
Return vs Industry: BRCT.F underperformed the US Biotechs industry which returned 14.6% over the past year.
Return vs Market: BRCT.F underperformed the US Market which returned 30.3% over the past year.
Price Volatility
| BRCT.F volatility | |
|---|---|
| BRCT.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: Data is not available.
Volatility Over Time: Insufficient data to determine BRCT.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 96 | Gunilla Osswald | www.bioarctic.se |
BioArctic AB (publ) develops biological drugs for patients with disorders of the central nervous system in Sweden. The company develops Lecanemab, Lecanemab AHEAD 3-45, and Lecanemab Back-up for the treatment of Alzheimer’s disease. In addition, the company develops AD-BT2802 and AD-BT2803 drug projects against Alzheimer’s disease that are being combined with blood-brain barrier technology and Brain Transporter to promote uptake of antibodies into the brain.
BioArctic AB (publ) Fundamentals Summary
| BRCT.F fundamental statistics | |
|---|---|
| Market cap | US$1.48b |
| Earnings (TTM) | -US$21.05m |
| Revenue (TTM) | US$15.08m |
98.2x
P/S Ratio-70.4x
P/E RatioIs BRCT.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BRCT.F income statement (TTM) | |
|---|---|
| Revenue | SEK 166.84m |
| Cost of Revenue | SEK 75.29m |
| Gross Profit | SEK 91.55m |
| Other Expenses | SEK 324.41m |
| Earnings | -SEK 232.86m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 13, 2025
| Earnings per share (EPS) | -2.63 |
| Gross Margin | 54.87% |
| Net Profit Margin | -139.57% |
| Debt/Equity Ratio | 0% |
How did BRCT.F perform over the long term?
See historical performance and comparison